List of works - Raphael A Itzykson

A landscape of germline mutations in a cohort of inherited bone marrow failure patients

scientific article published on 16 November 2017

A multiparametric niche-like drug screening platform in acute myeloid leukemia

scientific article published in 2022

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

scientific article published on 3 April 2014

Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease

scientific article published on 6 June 2014

Allogeneic hematopoietic cell transplantation following the use of hypomethylating agents among patients with relapsed or refractory AML: Findings from an international retrospective study.

scientific article published on 9 April 2018

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

scientific article published on September 2015

An evolutionary perspective on chronic myelomonocytic leukemia.

scientific article published on 05 April 2013

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

scientific article published on 26 January 2015

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

scientific article published on 31 July 2015

Applying ecological and evolutionary theory to cancer: a long and winding road ⬇️

scientific article published on 16 November 2012

Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM) ⬇️

scientific article published on March 15, 2013

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients

scientific article published on 06 February 2014

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

scientific article

Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

scientific article published on 20 March 2019

Bleeding in patients with Budd-Chiari syndrome

scientific article published on 20 August 2010

CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease

scientific article published on 20 January 2015

CMML: Clinical and molecular aspects.

scientific article

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

scientific article published on 7 April 2015

Choosing a hypomethylating agent in MDS: does gender matter?

scientific article

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

scientific article

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

scientific article published on 13 February 2015

Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?

scientific article published on October 2013

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

scientific article published on 14 April 2017

Clonal architecture of chronic myelomonocytic leukemias

scientific article published on 14 January 2013

Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy

scientific article published on 24 June 2020

Clonal interference of signaling mutations holds prognostic relevance in core binding factor acute myeloid leukemia.

scientific article published on 24 April 2018

Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML

scientific article published on 02 November 2018

Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation

scientific article

Diagnosis of ureaplasma urealyticum septic polyarthritis by PCR assay and electrospray ionization mass spectrometry in a patient with acute lymphoblastic leukemia.

scientific article

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

scientific article published on 15 December 2011

Epigenetics of myelodysplastic syndromes

scientific article

Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia

article

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

scientific article published in 2021

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

scholarly article by Ashfaq Ali et al published 26 February 2018 in Leukemia

Home spirometry in bronchiolitis obliterans after allogeneic haematopoietic cell transplant.

scientific article published on 19 July 2018

How I treat chronic myelomonocytic leukemia

scientific article published on June 2017

How and when to decide between epigenetic therapy and chemotherapy in patients with AML.

scientific article published in December 2017

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

scientific article published on 01 April 2018

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

scientific article published on 15 April 2011

Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria ⬇️

scientific article published on April 1, 2011

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

scientific article

Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality

scientific article published on 30 July 2020

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.

scientific article published on 16 January 2013

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort ⬇️

scientific article published on June 21, 2012

MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.

scientific article

Macrophage migration inhibitory factor is overproduced through EGR1 in TET2<sup>low</sup> resting monocytes

scientific article published on 03 February 2022

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study

scientific article published on 04 March 2020

Meeting report: myelodysplastic syndromes at ASH 2007.

scientific article published on 6 March 2008

Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.

scientific article published on 26 September 2014

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

scientific article

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

scientific article published on 24 February 2016

Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.

scientific article published on 18 June 2013

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

scientific article published on 26 February 2018

Myelodysplastic syndromes

scientific article published on 21 March 2014

New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.

scientific article published on 26 June 2015

Novel M-component based biomarkers in Waldenström's macroglobulinemia

scientific article published on 01 February 2011

Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation.

scientific article

Optimal sequencing of treatments for patients with myelodysplastic syndromes

scientific article published on March 2009

Optimizing hypomethylating agents in myelodysplastic syndromes

scientific article published on March 2012

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure ⬇️

scientific article published on July 25, 2011

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

scientific article published on 02 July 2018

Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents

scientific article published on 31 January 2012

Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine

scientific article published on 12 February 2013

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

scientific article published on 25 April 2018

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

scientific article published on 12 October 2010

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

scientific article

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

scientific article published on 24 August 2017

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

scientific article published on 24 June 2013

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

scientific article published on 5 February 2013

Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia.

scientific article published in May 2008

Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?

scientific article published on 28 February 2020

Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie C

scientific article

Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.

scientific article published on December 2013

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.

scientific article published in November 2012

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

scientific article published on 01 December 2012

Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine

scientific article published on October 2012

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

scientific article published on 27 July 2010

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

scientific article (publication date: 25 June 2004)

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.

scientific article

[Hypomethylating agents for the treatment of myelodysplastic syndromes]

scientific article published on 01 August 2011

List of works by Raphael A Itzykson

A landscape of germline mutations in a cohort of inherited bone marrow failure patients

A multiparametric niche-like drug screening platform in acute myeloid leukemia

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease

Allogeneic hematopoietic cell transplantation following the use of hypomethylating agents among patients with relapsed or refractory AML: Findings from an international retrospective study.

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

An evolutionary perspective on chronic myelomonocytic leukemia.

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

Applying ecological and evolutionary theory to cancer: a long and winding road ⬇️

Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM) ⬇️

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

Bleeding in patients with Budd-Chiari syndrome

CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease

CMML: Clinical and molecular aspects.

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Choosing a hypomethylating agent in MDS: does gender matter?

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Clonal architecture of chronic myelomonocytic leukemias

Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy

Clonal interference of signaling mutations holds prognostic relevance in core binding factor acute myeloid leukemia.

Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML

Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation

Diagnosis of ureaplasma urealyticum septic polyarthritis by PCR assay and electrospray ionization mass spectrometry in a patient with acute lymphoblastic leukemia.

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Epigenetics of myelodysplastic syndromes

Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

Home spirometry in bronchiolitis obliterans after allogeneic haematopoietic cell transplant.

How I treat chronic myelomonocytic leukemia

How and when to decide between epigenetic therapy and chemotherapy in patients with AML.

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria ⬇️

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort ⬇️

MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.

Macrophage migration inhibitory factor is overproduced through EGR1 in TET2<sup>low</sup> resting monocytes

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study

Meeting report: myelodysplastic syndromes at ASH 2007.

Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

Myelodysplastic syndromes

New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.

Novel M-component based biomarkers in Waldenström's macroglobulinemia

Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation.

Optimal sequencing of treatments for patients with myelodysplastic syndromes

Optimizing hypomethylating agents in myelodysplastic syndromes

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure ⬇️

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents

Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia.

Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?

Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie C

Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.